{"id":"W2947096198","doi":"10.1200/jco.2019.37.15_suppl.5521","title":"Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Ozmosis Research (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Oncology; PARP inhibitor; BRCA mutation; Progression-free survival; Ovarian cancer; Clinical trial; Phases of clinical research; Cancer; Response Evaluation Criteria in Solid Tumors; Progressive disease; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001522278,0.0006920455,0.0008727941,0.0002806403,0.0003063406,0.0006985988,0.0005636404,0.0009187926,0.005439108],"category_scores_gemma":[0.0007603782,0.000277965,0.0006087071,0.0002965975,0.0006042275,0.0005837083,0.0004645167,0.001939663,0.0006583649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008652429,"about_ca_system_score_gemma":0.001065245,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006670588,"about_ca_topic_score_gemma":0.002885885,"domain_scores_codex":[0.9996705,0.0001699303,0.0000149135,0.0000441091,0.00004027878,0.00006024849],"domain_scores_gemma":[0.9995621,0.00006901967,0.00009511888,0.00004051773,0.00002369255,0.0002095756],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.734206,0.03917462,0.01816267,0.00133187,0.001045798,0.0006528253,0.0004440785,0.00289946,0.02786392,0.001041626,0.01313005,0.160047],"study_design_scores_gemma":[0.7244484,0.227979,0.02902275,0.00006734888,0.0003720779,0.0006066139,0.00009155352,0.001671222,0.003481543,0.0006912948,0.01153659,0.00003154587],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9821149,0.002780628,0.0005456723,0.001025936,0.00008775353,0.005226807,0.002598305,0.0001183508,0.005501546],"genre_scores_gemma":[0.9743562,0.001725279,0.002883847,0.002375012,0.0002057919,0.004800959,0.006204078,0.00003952577,0.007409277],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005439108,"threshold_uncertainty_score":0.01819563,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.155816727927704,"score_gpt":0.5288553929845182,"score_spread":0.3730386650568142,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}